RE:RE:RE:RE:RE:we already have several pieces of news incoming this quarterYou can find so many of these NR with fixed dates provided and they have missed so many of the dates. What is your point?
They should just say nothing and surprise all when they finally submit it. This is the third date provided by "New Management" as the NewcamoRealstups IDs liked to tell us not long ago.
ualcin1 wrote: In its June 30 PR, Liminal states the following:
| “We now expect the following timing for two important priorities of the Company for 2020: - The re-submission of our biologics licensing application (BLA) with the US Food and Drug Administration (FDA) for Ryplazim® (plasminogen) for the treatment of congenital plasminogen deficiency is anticipated to be filed in the third quarter of 2020; and
- Our multiple ascending dose (MAD) Phase 1 clinical study of fezagepras is expected to be initiated in the second half of 2020.”
|